Business Wire

NJ-SOLIDIA-TECHNOLOGIES

15.10.2020 15:02:08 CEST | Business Wire | Press release

Share
Solidia Technologies Announces Possibility of Turning Concrete into a Carbon Sink for the Planet

Solidia Technologies® CEO Tom Schuler shared the possibility of turning Solidia Concrete into a carbon sink for the planet during his TED Talk at TED and Future Stewards’ Global Countdown Launch. Tom was invited to "The Countdown," a call to action on climate change, to explain how cement and concrete contribute to the global carbon challenge and the potential impact of new production technologies for Solidia Cement™ and Solidia Concrete™.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201015005299/en/

"To address global warming, innovation in both cement production and carbon utilization are absolutely essential," said Tom. "Our new technology for ready-mix concrete is currently being tested for infrastructure applications. And we have already pushed our research beyond that with a technology that enables concrete to become a carbon sink; that means we consume more carbon dioxide (CO2 ) than we emit during production."

Outlining the issue, he explained how concrete contributes to the global carbon challenge because it is made with cement. "For every ton of cement produced, about a ton of CO2 is released into the atmosphere. As a result, the cement industry is the second largest industrial emitter of CO2 , responsible for about eight percent of global emissions."

By changing the chemistry of cement, Solidia both lowers emissions at the cement plant and consumes CO2 in the production of concrete. "Our cement reacts with CO2 instead of water. During curing, the chemical reaction with our cement breaks apart the CO2 molecules and captures the carbon to make limestone that glues the concrete together.”

For production of precast concrete that is cured in kilns, he explained: “When you combine the emissions reduction during cement production with CO2 consumption during curing, we reduce cement’s carbon footprint by up to 70%.”

Describing the different carbon delivery system developed for ready-mix, he added: "Since we can’t use CO2 gas at a construction site, we had to introduce it into our concrete in solid or liquid form. We are partnering with companies that are turning waste CO2 into a family of chemicals, like oxalic or even citric acid – the same one in orange juice. We use these acids to react with our cement and pack in as much as four times more carbon, resulting in carbon-negative concrete.”

Citing the potential impact, Tom explained: “That means that, in just a few hours, one kilometer of road could permanently consume the same amount of CO2 that nearly 100,000 trees absorb in one year. Thanks to chemistry and waste CO2 , we have the potential to transform concrete – the second most utilized material on the planet – into a carbon sink for the planet.”

About Solidia Technologies®

Based in Piscataway, N.J. (USA), Solidia Technologies® is a cement and concrete technology company that makes it easy and profitable to use CO2 to create superior and sustainable building and construction materials. At scale each year, Solidia can eliminate at least 1.5 gigatonnes of CO₂, save three trillion liters of fresh water, reduce energy consumption equal to ~260 million barrels of oil, and eliminate 100 million tonnes of concrete landfill waste, while engaging industry in a rapid, globally scalable response to some of the greatest threats facing people and planet. Solidia’s investors include Kleiner Perkins , Bright Capital , BASF , BP , Lafarge Holcim , Total Energy Ventures , Oil and Gas Climate Initiative (OGCI) Climate Investments , Air Liquide , Bill Joy and other private investors. Honors include: the 2020, 2019 and 2014 Global Cleantech 100 ; a 2020 and 2014 Best Place to Work in NJ ; 2020, 2019 and 2018 BP Advancing Low Carbon accreditation; the 2019 Solar Impulse 1000 Efficient Solutions ; 2017 ERA Grand Challenge (formerly CCEMC) finalist; 2016 Sustainia 100 ; 2015 NJBiz Business of the Year; 2014 CCEMC Grand Challenge finalist; 2013 R&D Top 100 ; 2013 Katerva Award finalist; and MIT’s Climate CoLab shortlist. Follow Solidia on LinkedIn , Instagram , Twitter , and YouTube .

About TED

TED is a nonprofit organization devoted to Ideas Worth Spreading, often in the form of short talks delivered by leading thinkers and doers. Many of these talks are given at TED conferences, intimate TED Salons and thousands of independently organized TEDx events around the world. Videos of these talks are made available, free, on TED.com and other platforms. Audio versions of TED Talks are published to TED Talks Daily , available on all podcast platforms.

Follow TED on Twitter , Facebook , Instagram and on LinkedIn . Connect at Countdown@ted.com .

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Wyss Geneva Steps Into Its Next Chapter11.6.2026 13:33:00 CEST | Press release

Dr. Tracy Laabs named Director; Prof. Dr. Erwin Böttinger honored for his transformative leadership The Wyss Center for Bio and Neuroengineering in Geneva is pleased to announce the appointment of Dr. Tracy Laabs as Director, effective July 1st 2026. Dr. Laabs succeeds Prof. Dr. Erwin Böttinger, who leaves behind a fundamentally transformed organization: one that no longer just pursues breakthrough science but systematically turns it into ventures that reach patients. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260611328520/en/ Dr. Tracy Laabs, incoming Director, Wyss Center Geneva Since joining the Wyss Center as Director in April 2023, Prof. Böttinger brought a bold vision: to evolve the Center from a portfolio of promising projects into a disciplined engine for venture creation. Under his leadership, the Center spun off six companies in two years (including ABILITY Neurotech SA and Clee Medical SA in 2025) while simult

BeOne Showcases Landmark Phase 3 Data in CLL Patients Aged 80+ at EHA 2026, Reinforcing BRUKINSA Benefit11.6.2026 13:24:00 CEST | Press release

Nearly two-thirds of patients aged 80+ treated with BRUKINSA remained progression-free at six years, despite advanced age and high-risk featuresNew European patient research reveals safety, disease severity, and effectiveness are the top drivers for first-line CLL treatment decisions – not time on therapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced the presentation of a large Phase 3 dataset in patients with chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL) aged 80 and older, showing sustained benefit with BRUKINSA after nearly 6.5 years of follow-up, reinforcing its role as the foundational BTK inhibitor. BRUKINSA is the only BTK inhibitor to demonstrate superior efficacy vs. ibrutinib in a Phase 3 trial.1 These data, one of the largest datasets of older patients with treatment-naive CLL, will be presented at the 2026 European Hematology Association (EHA) Congress in Stockholm, Sweden. Amit Agarwal, M.D.,

Takeda’s Zasocitinib Significantly Outperforms Deucravacitinib in Head-to-Head Phase 3 Psoriasis Study, Promising to Redefine Oral Treatment Expectations11.6.2026 13:00:00 CEST | Press release

Once-daily oral zasocitinib demonstrated statistical superiority over deucravacitinib for all primary and key secondary endpoints in plaque psoriasis study More than 35% of zasocitinib-treated patients achieved complete skin clearance (PASI 100) at week 16 – more than 2.5 times the response rate for deucravacitinib Safety profile was consistent with previous studies with no new safety signals identified Takeda (TSE:4502/NYSE:TAK) announced positive topline results for the Phase 3, randomized, multicenter, double-blind study comparing zasocitinib (TAK-279), an investigational, next-generation, highly selective and potent oral tyrosine kinase 2 (TYK2) inhibitor, to deucravacitinib in adults with moderate-to-severe plaque psoriasis (PsO). In the LATITUDE Atlas (TAK-279-PsO-3004) head-to-head study, zasocitinib demonstrated statistical superiority over deucravacitinib for the primary endpoint, Psoriasis Area and Severity Index (PASI) 100 response rate at week 16. The study also demonstrate

Clearlake Expands Liquid Credit Platform With Acquisition of LCM Asset Management’s CLO Contracts11.6.2026 13:00:00 CEST | Press release

Transaction adds 31 CLOs and more than $5 billion of AUM, strengthening Clearlake Credit’s position in liquid credit Clearlake Capital Group, L.P. (“Clearlake” or the “Firm”), a global investment firm managing integrated platforms spanning private equity, liquid and private credit, and other related strategies, today announced that its credit platform, Clearlake Credit, will assume management of CLOs managed by LCM Asset Management, LLC. The transaction adds 31 CLOs representing more than $5 billion of assets under management and increases assets managed by Clearlake Credit to approximately $39 billion across liquid credit, private credit, and other customized credit solutions. The acquisition further broadens the Firm’s capabilities, deepens its relationships with institutional investors, and reinforces its client-centric approach and commitment to seeking attractive risk-adjusted returns across market cycles. Milbank LLP and Dechert LLP represented Clearlake Credit in the transaction

L&T Technology Services, Databricks Partner to Deliver Industrial AI at Scale for Asset-Intensive Industries11.6.2026 12:30:00 CEST | Press release

Partnership brings together LTTS’ expertise in its Sustainability segment and the Databricks platform to accelerate Engineering Intelligence across industrial operations. L&T Technology Services (BSE: 540115, NSE: LTTS), a global leader in AI, Digital & ER&D Consulting Services, today announced a strategic go-to-market partnership with Databricks, the leading Data and AI company, to co-develop and deliver Industrial AI solutions that advance Engineering Intelligence (EI) for asset-intensive enterprises. Anchored in LTTS' Sustainability segment, spanning Process Engineering, Discrete Manufacturing and Industrial Products, the partnership will support Energy, Petrochemicals and Industrials clients globally. As industrial organizations seek to unlock greater value from decades of operational and engineering data, the alliance will combine LTTS’ deep domain capabilities with the Databricks platform to transform complex plant data into Engineering Intelligence - enabling improved asset reli

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye